168 related articles for article (PubMed ID: 10339327)
1. End-stage renal disease: managing quality and cost.
Li C
Health Care Innov; 1998; 8(6):32-3. PubMed ID: 10339327
[No Abstract] [Full Text] [Related]
2. Medicare coverage changes force a DM approach to ESRD.
Healthc Demand Dis Manag; 1998 Dec; 4(12):184-6. PubMed ID: 10339124
[TBL] [Abstract][Full Text] [Related]
3. Managed care is not the "cure-all" for improving quality and controlling costs in ESRD.
Amerling R
Nephrol News Issues; 1999 Apr; 13(4):46-7. PubMed ID: 10418448
[No Abstract] [Full Text] [Related]
4. Should the exception be lifted that disallows ESRD patients from enrolling in managed care programs?
McCarthy D
Nephrol News Issues; 1999 Oct; 13(10):12-3, 20. PubMed ID: 10827670
[No Abstract] [Full Text] [Related]
5. Don't overlook disease management programs for low-incidence, high-cost diseases to improve your bottom line.
Bruce D; Dickmeyer J
J Health Care Finance; 2001; 28(2):45-9. PubMed ID: 11794756
[TBL] [Abstract][Full Text] [Related]
6. The organization of medical care. Lessons from the Medicare end stage renal disease program.
Levinsky NG
N Engl J Med; 1993 Nov; 329(19):1395-9. PubMed ID: 8413437
[No Abstract] [Full Text] [Related]
7. Overview of the Medicare and Medicaid programs.
Hoffman ED; Klees BS; Curtis CA
Health Care Financ Rev Stat Suppl; 2002; ():1-378. PubMed ID: 15630768
[No Abstract] [Full Text] [Related]
8. Adapting to changes in Medicare cost report requirements.
Rossi T
Nephrol News Issues; 2005 Sep; 19(10):36-9. PubMed ID: 16187645
[No Abstract] [Full Text] [Related]
9. Managing chronic kidney disease.
Amedia CA
Manag Care; 2003 Apr; Spec No():8-12; discussion 17-20. PubMed ID: 12751138
[No Abstract] [Full Text] [Related]
10. The direction of end-stage renal disease reimbursement in the United States.
Lockridge RS
Semin Dial; 2004; 17(2):125-30. PubMed ID: 15043614
[TBL] [Abstract][Full Text] [Related]
11. Payment for quality in end-stage renal disease.
Himmelfarb J; Pereira BJ; Wesson DE; Smedberg PC; Henrich WL
J Am Soc Nephrol; 2004 Dec; 15(12):3263-9. PubMed ID: 15579531
[No Abstract] [Full Text] [Related]
12. Prescription drugs in Medicare and the ESRD program.
Powe NR
Semin Nephrol; 2000 Nov; 20(6):535-42. PubMed ID: 11111855
[TBL] [Abstract][Full Text] [Related]
13. Lessons from Arizona on managing costs.
Hawryluk M
Provider; 1996 Jul; 22(7):23-4. PubMed ID: 10161973
[No Abstract] [Full Text] [Related]
14. The politics of health cost containment: end-stage renal disease.
Rettig RA
Bull N Y Acad Med; 1980; 56(1):115-38. PubMed ID: 6986928
[No Abstract] [Full Text] [Related]
15. The medical directorship of renal dialysis facilities under the new Medicare conditions for coverage: challenges and opportunities.
DeOreo PB
Blood Purif; 2009; 27(1):16-21. PubMed ID: 19169012
[TBL] [Abstract][Full Text] [Related]
16. Surviving change: Can the ESRD provisions in the SCHIP create a level playing field?
Gardner AV
Nephrol News Issues; 2007 Sep; 21(10):52-3. PubMed ID: 17918480
[No Abstract] [Full Text] [Related]
17. Options for dialysis providers in a global capitated environment.
Westman J; George S; Scheel PJ; McMurray SD; Pulliam J
Nephrol News Issues; 1996 Sep; 10(9):26-31. PubMed ID: 9004663
[No Abstract] [Full Text] [Related]
18. The public cost of kidney disease.
Ruchlin HS
Soc Work Health Care; 1984; 9(4):1-9. PubMed ID: 6385310
[TBL] [Abstract][Full Text] [Related]
19. Conditions for coverage fail to relieve administrative burden.
Wish D
Nephrol News Issues; 2005 Sep; 19(10):46-7, 51. PubMed ID: 16187648
[No Abstract] [Full Text] [Related]
20. Medicare demonstration project creeping to the starting line.
Capitation Manag Rep; 2004 Oct; 11(10):109-11. PubMed ID: 15566118
[No Abstract] [Full Text] [Related]
[Next] [New Search]
